HOOK

Hookipa Pharma Inc. (HOOK) | Rumor.io

Hookipa Pharma

HOOK

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.33

Market capitalization14M

Earnings per share-4.83

Dividend yield (TTM)—

Revenue (annual)43.9M

Net income (annual)-43.5M

Social

What share of all stock conversation is about HOOK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 22

HOOKIPA Pharma Inc. (HOOK) entered into an Asset Purchase Agreement with Gilead Sciences to sell assets related to its HB-400 and HB-500 programs for up to $10 million.
The company's board voted to liquidate and shut down all programs, with Gilead acquiring the assets and HOOKIPA Pharma Inc. potentially dissolving.
HOOKIPA Pharma Inc. has approximately 12.54 million outstanding shares and $40 million in cash, with Gilead's offer potentially delivering a share price to shareholders if the company decides to dissolve.

Generated by AI

Sentiment

Of the messages about HOOK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.44% +6.97
Bearish	—	—	—	9.56% -6.97

Bullish· Jun 4

HOOKIPA Pharma's Phase 2 results show promise for its immunotherapy drug HB-200 in head and neck cancer.
The company's valuation is undervalued compared to its cash position, making it an attractive investment opportunity.
Preliminary PFS data for HB-200 shows a 16.3-month survival benefit, indicating durable disease control and a potential buyout from Gilead.

Bearish· May 24

The stock's price action is considered absurd and extreme, with a significant decline of 18.36%.
The company's short interest is high, with some users suggesting that shorts are getting an advantage over the company.
The stock's recent price drop is seen as a buying opportunity, with some users accumulating shares at lower prices and expecting the stock to revisit its previous level of $1.

Generated by AI

Topics

Of the messages about HOOK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	46.38%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	53.62%

Announcements· Jul 10

HOOKIPA Pharma Inc. (HOOK) will undergo a 1-for-10 reverse stock split, reducing shares outstanding to 1.46M from 14.6M.
The reverse stock split will also reduce HOOK's share float to 7.8M from 77.6M.
The reverse stock split is part of a larger trend, as Fresenius (FRES) has also announced a 1-for-10 reverse stock split, reducing its shares outstanding to 1.46M from 14.6M.

Technical Analysis· Dec 22

$HOOK is showing a potential breakout with a weekly chart curling up and a target of $2.05.
The stock is forming a falling wedge into a cup and handle, with a possible slow grind back down before the next big news comes out.
The 30m MACD is turning green, setting up a perfect buy opportunity, with buy orders in at the 200sma and a large buy of shares at 1.41/share.

Generated by AI

Community

Of the messages about HOOK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	24.2%
Newcomers	—	—	—	75.8%

Regulars· Jul 22

The largest shareholder, Artal, has increased its holding of HOOK by 463% to 5.666m shares, making it another significant owner.
HOOKIPA Pharma's trading has been below cash value, and management has been given time to address this since the end of 2023, with a potential outright sale seeming likely.
The company is now effectively for sale, as indicated by management's statement of wanting to enhance shareholder value, likely with the involvement of investment bankers to run a process, which may lead to a buyout.

Newcomers· Jan 10

Many newcomers are focusing on the significant price increase of HOOKIPA Pharma Inc., with some observing a 25% rise from $1.85 to $2.32.
There is concern among newcomers that Gilead may acquire HOOKIPA Pharma Inc. in the future, with some mentioning a potential merger.
Some newcomers are speculating about the company's fundamentals and algorithm-driven price movements, with a few suggesting that the stock's fundamentals will propel it to higher prices.

Generated by AI

Also Discussed

Investors talking about HOOK also mention

#	Name	Attention
1	PDS Biotechnology CorporationPDSB	0%-0.01
2	EFTR - eFFECTOR Therapeutics, Inc.	——
3	HARP - Harpoon Therapeutics, Inc.	——
4	MRUS - Merus N.V.	——
5	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
6	BCEL - Atreca, Inc.	——
7	KAVL - Kaival Brands Innovations Group, Inc.	——
8	ACHL - Achilles Therapeutics plc	——
9	PBLA - Panbela Therapeutics, Inc.	——
10	Universal Security Instruments Inc.UUU	0%new

Hookipa Pharma Inc.

Healthcare
Biotechnology

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies engineered to target infectious diseases and cancer. Headquartered in New York City, the company focuses on leveraging its proprietary arenavirus platform technology to create novel vaccine candidates. This platform is designed to induce potent and targeted immune responses by simulating a natural viral infection without causing disease. Hookipa Pharma primarily targets oncology and infectious disease sectors, aiming to address unmet medical needs through robust and durable immune stimulation. The company's approach enables the development of potential treatments that can be more effective and have fewer side effects compared to traditional vaccines and therapies. In the financial market, Hookipa Pharma Inc. serves as an intriguing entity for stakeholders interested in cutting-edge biopharmaceutical research and development, holding considerable potential impact on public health and therapeutic innovation.

Website

Location

350 Fifth Avenue

New York, NY, 10118

United States

Social

What share of all stock conversation is about HOOK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 22

HOOKIPA Pharma Inc. (HOOK) entered into an Asset Purchase Agreement with Gilead Sciences to sell assets related to its HB-400 and HB-500 programs for up to $10 million.
The company's board voted to liquidate and shut down all programs, with Gilead acquiring the assets and HOOKIPA Pharma Inc. potentially dissolving.
HOOKIPA Pharma Inc. has approximately 12.54 million outstanding shares and $40 million in cash, with Gilead's offer potentially delivering a share price to shareholders if the company decides to dissolve.

Generated by AI

Sentiment

Of the messages about HOOK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.44% +6.97
Bearish	—	—	—	9.56% -6.97

Bullish· Jun 4

HOOKIPA Pharma's Phase 2 results show promise for its immunotherapy drug HB-200 in head and neck cancer.
The company's valuation is undervalued compared to its cash position, making it an attractive investment opportunity.
Preliminary PFS data for HB-200 shows a 16.3-month survival benefit, indicating durable disease control and a potential buyout from Gilead.

Bearish· May 24

The stock's price action is considered absurd and extreme, with a significant decline of 18.36%.
The company's short interest is high, with some users suggesting that shorts are getting an advantage over the company.
The stock's recent price drop is seen as a buying opportunity, with some users accumulating shares at lower prices and expecting the stock to revisit its previous level of $1.

Generated by AI

Topics

Of the messages about HOOK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	46.38%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	53.62%

Announcements· Jul 10

HOOKIPA Pharma Inc. (HOOK) will undergo a 1-for-10 reverse stock split, reducing shares outstanding to 1.46M from 14.6M.
The reverse stock split will also reduce HOOK's share float to 7.8M from 77.6M.
The reverse stock split is part of a larger trend, as Fresenius (FRES) has also announced a 1-for-10 reverse stock split, reducing its shares outstanding to 1.46M from 14.6M.

Technical Analysis· Dec 22

$HOOK is showing a potential breakout with a weekly chart curling up and a target of $2.05.
The stock is forming a falling wedge into a cup and handle, with a possible slow grind back down before the next big news comes out.
The 30m MACD is turning green, setting up a perfect buy opportunity, with buy orders in at the 200sma and a large buy of shares at 1.41/share.

Generated by AI

Community

Of the messages about HOOK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	24.2%
Newcomers	—	—	—	75.8%

Regulars· Jul 22

The largest shareholder, Artal, has increased its holding of HOOK by 463% to 5.666m shares, making it another significant owner.
HOOKIPA Pharma's trading has been below cash value, and management has been given time to address this since the end of 2023, with a potential outright sale seeming likely.
The company is now effectively for sale, as indicated by management's statement of wanting to enhance shareholder value, likely with the involvement of investment bankers to run a process, which may lead to a buyout.

Newcomers· Jan 10

Many newcomers are focusing on the significant price increase of HOOKIPA Pharma Inc., with some observing a 25% rise from $1.85 to $2.32.
There is concern among newcomers that Gilead may acquire HOOKIPA Pharma Inc. in the future, with some mentioning a potential merger.
Some newcomers are speculating about the company's fundamentals and algorithm-driven price movements, with a few suggesting that the stock's fundamentals will propel it to higher prices.

Generated by AI

Hookipa Pharma

Social

May 22

Sentiment

Bullish· Jun 4

Bearish· May 24

Topics

Announcements· Jul 10

Technical Analysis· Dec 22

Community

Regulars· Jul 22

Newcomers· Jan 10

Also Discussed

Hookipa Pharma Inc.

Company Information

Location

Also Discussed

Social

May 22

Sentiment

Bullish· Jun 4

Bearish· May 24

Topics

Announcements· Jul 10

Technical Analysis· Dec 22

Community

Regulars· Jul 22

Newcomers· Jan 10